Showing 1,664 news articles about Hepatitis & HIV

Filters Content type: Editors' picks Topic: Hepatitis & HIV

Hepatitis A, B and C are viral infections that can damage the liver and cause serious illnesses. Co-infection with HIV and hepatitis B or C is quite common. Safe and effective treatments are available.

New & experimental hepatitis C treatment

Copy of New second generation combination therapy for HCV - first or best in the market

Editor's pick
Seeking Alpha
19 November 2012
New & experimental hepatitis C treatment

Gilead may move ahead of rivals with hepatitis C results

Editor's pick
Bloomberg Businessweek
15 November 2012
New & experimental hepatitis C treatment

Copy of Gilead may move ahead of rivals with hepatitis C results

Editor's pick
Bloomberg Businessweek
15 November 2012
New & experimental hepatitis C treatment

Bristol-Myers Squibb’s Investigational Hepatitis C Compounds Lambda and Daclatasvir Plus Ribavirin Achieved SVR12 in 93% of Genotype 1b Treatment-Naive Patients In Phase IIb Study

Editor's pick
HCV New Drugs Research
14 November 2012
New & experimental hepatitis C treatment

Gilead May Top Rivals With Hepatitis C Therapy Results

Editor's pick
Bloomberg BusinessWeek
14 November 2012
New & experimental hepatitis C treatment

Abbott Announces Phase 3 Interferon-free Hepatitis C Regimens to be Studied in Broad Patient Populations

Editor's pick
Abbott press release
14 November 2012
Hepatitis C symptoms & diagnosis

Background liver proliferation linked to noncirrhotic HCC in patients with HCV

Editor's pick
Healio Hepatology
13 November 2012
New & experimental hepatitis C treatment

Achillion Provides Update on Clinical HCV Development Programs

Editor's pick
Achillion press release
13 November 2012
New & experimental hepatitis C treatment

Hep C Competitors Cede Space To Gilead And Bristol-Myers And Turn To Niche Uses

Editor's pick
Seeking Alpha
13 November 2012
New & experimental hepatitis C treatment

Gilead Climbs on Study Results of Hepatitis C Combination

Editor's pick
Bloomberg
12 November 2012
New & experimental hepatitis C treatment

Novartis' Certican succeeds in liver transplant trial

Editor's pick
Reuters
12 November 2012
New & experimental hepatitis C treatment

AASLD-GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients

Editor's pick
HCV New Drugs Research
12 November 2012
New & experimental hepatitis C treatment

Gilead, Abbott Unwrap Dueling Hep C Pill Data

Editor's pick
The Street
12 November 2012
New & experimental hepatitis C treatment

ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for Hepatitis C

Editor's pick
Vertex press release
11 November 2012
Cancer

The connection between Fatty Liver Disease and the Increase in the Rate of Liver Cancer

Editor's pick
AASLD press release
11 November 2012
New & experimental hepatitis C treatment

Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily

Editor's pick
Vertex press release
11 November 2012
New & experimental hepatitis C treatment

Boehringer Ingelheim to start late-stage hepatitis C drug trial

Editor's pick
Reuters
11 November 2012
New & experimental hepatitis C treatment

Idenix Reports On IDX719 and IDX184

Editor's pick
Idenix press release
11 November 2012
Hepatitis C transmission & prevention

Hepatitis C-Safeguarding the Medical Injection Process

Editor's pick
HCV New Drugs Research
10 November 2012
People who inject drugs

UK: HPA report found half of people who inject drugs are infected with hepatitis C, one in 100 have HIV

Editor's pick
Health Protection Agency
10 November 2012
Hepatitis C transmission & prevention

Europe Fails to Screen its Population for Hepatitis

Editor's pick
PR Newswire
8 November 2012
Hepatitis C transmission & prevention

UK lags behind Germany France and Slovenia in international index on hepatitis care performance

Editor's pick
Hepatitis C Trust
8 November 2012
New & experimental hepatitis C treatment

Copy of Merck will initiate interferon-free Phase II clinical trials for MK-5172, an investigational, once-daily, oral treatment for chronic hepatitis C virus

Editor's pick
Merck press release
6 November 2012
New & experimental hepatitis C treatment

Merck will initiate interferon-free Phase II clinical trials for MK-5172, an investigational, once-daily, oral treatment for chronic hepatitis C virus

Editor's pick
Merck press release
6 November 2012